Pura Vida Investments takes a passive position in Lyra Therapeutics (LYRA)

0

Fintel reports that Pura Vida Investments, Llc has filed a Form 13G with the SEC disclosing ownership of 2,782,091 shares of Lyra Therapeutics Inc (LYRA). This represents 8.74% of the company.

In its previous filing, the company said it held 520,544 shares, representing a raise about 80%. The company increased its portfolio allocation in LYRA by more than 1,000% in the last quarter.

Pura Vida Investments is a healthcare investment company that invests in medical technologies, genomics, biopharma and health technologies.

What are the other big shareholders doing?

Perceptive Advisors Llc holds 9,146,730 shares representing 28.74% ownership of the company. In its previous filing, the company said it held 3,222,560 shares, representing a raise of 64.77%. The company increased its portfolio allocation in LYRA by 523.74% in the last quarter.

Nantahala Capital Management, LLC holds 2,369,668 shares representing 7.45% ownership of the company.

Samsara BioCapital, LLC owns 1,777,251 shares representing 5.58% ownership of the company.

VR Adviser, LLC owns 924,170 shares representing 2.90% ownership of the company.

What is the general institutional feeling?

There are 56 funds or institutions reporting positions at Lyra Therapeutics Inc. This is an increase of nine owner(s) or 19.15%.

Average portfolio weight of all funds dedicated to Lyra Therapeutics Inc is 0.1479%, an increase of 755%. The total number of shares held by institutions has increased over the past three months by 278.07% to 19,455,285 shares.

Based on this information, institutional sentiment is bullish.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Share.

Comments are closed.